Follow The Filings

FULC Fulcrum Therapeutics Inc.

Health Care, filed as FULCRUM THERAPEUTICS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

  • 1 exit

In 2026 Q2 Nathan Fischel sold out of Fulcrum Therapeutics.

Who owns FULC

Sorted by value, long equity only, as of 2026 Q2.

History
Nathan Fischel, Dafna Capital Management exited 2026 Q2 Last 2026 Q1 0.36% Exit −0.36% 205,000 $1.6M History

0 current, 1 exited last period, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by FULC's executives, directors and 10% owners in the last 12 months, from their Form 4s

All FULC insider trades
  • $1.5M bought by 1 insider
  • $58.4M sold by 1 insider outside a trading plan
  • $600K sold by 3 insiders under 10b5-1 plans
  1. Kevin Tang 10% owner, +1 joint filer
    Buy
    $595K 167,616 shares at $3.55 +2.4% to stake
    Traded Jul 16–17 Filed Jul 20
    ↗
  2. Kevin Tang 10% owner, +1 joint filer
    Buy
    $891K 249,946 shares at $3.57 +3.8% to stake
    Traded Jul 13–15 Filed Jul 15
    ↗
  3. Alan Ezekowitz Director
    Planned sale
    $66K 18,000 shares at $3.65 62% of stake
    Traded Jun 26 Filed Jun 30
    ↗
  4. Robert J Gould Director
    Planned sale
    $163K 15,000 shares at $10.87 3.1% of stake
    Traded Jan 2 Filed Feb 4
    ↗
  5. Robert J Gould Director
    Planned sale
    $161K 15,000 shares at $10.72 3.2% of stake
    Traded Feb 2 Filed Feb 4
    ↗
  6. Curtis Gale Oltmans Chief Legal Officer
    Planned sale
    $45K 3,452 shares at $12.92 25% of stake
    Traded Dec 15, 2025 Filed Dec 17, 2025
    ↗
  7. Ra Capital Management, L.P. 10% owner, +3 joint filers
    Sale
    $58.4M 4,175,139 shares at $13.98 41% of stake
    Traded Dec 8, 2025 Filed Dec 10, 2025
    ↗
  8. Robert J Gould Director
    Planned sale
    $165K 15,000 shares at $11.03 3% of stake
    Traded Nov 19, 2025 Filed Nov 21, 2025
    ↗

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 1.01,3.02,5.01,5.02,7.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 5.02 Filing Doc
SCHEDULE 13G — Filing Doc
10-Q Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
8-K 5.07 Filing Doc
8-K 5.02 Filing Doc
SCHEDULE 13G — Filing Doc
8-K 2.05,8.01 Filing Doc
8-K 8.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
8-K 1.02,2.02,5.02,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 4 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Net income -$97.34M -$9.72M -$74.88M

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $242.2M $249.92M $357.48M
Total non-current assets * $15.5M $10.8M $8.8M
Total assets $257.69M $260.72M $366.28M
Total current liabilities $13.68M $11.04M $13.05M
Total non-current liabilities * $8.83M $6.64M $4.24M
Total equity $235.19M $243.03M $349M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$90.96M -$2.22M -$60.06M
Cash from investing -$36.69M $32.23M $30.72M
Cash from financing $118.12M $2.75M $168.67M
Net change in cash -$9.54M $32.76M $139.32M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.